Patents by Inventor Mark Peter Ridgill

Mark Peter Ridgill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF METTL3
    Publication number: 20240101589
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: W—X—Y—Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Application
    Filed: October 7, 2021
    Publication date: March 28, 2024
    Inventors: DAVID JAMES HARDICK, Wesley Peter Blackaby, Elizabeth Jane Thomas, Frederick Arthur Brookfield, Jon Shepherd, Christian Bubert, Mark Peter Ridgill
  • METTL3 INHIBITORY COMPOUNDS
    Publication number: 20230391770
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Application
    Filed: October 5, 2021
    Publication date: December 7, 2023
    Inventors: David James Hardick, Wesley Peter Blackaby, Elizabeth Jane Thomas, Frederick Arthur Brookfield, Jon Shepherd, Christian Bubert, Mark Peter Ridgill
  • Polyheterocyclic compounds as METTL3 inhibitors
    Patent number: 11725010
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z??(I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: August 15, 2023
    Assignee: Storm Therapeutics Limited
    Inventors: Wesley Peter Blackaby, Elizabeth Jane Thomas, David James Hardick, Jon Shepherd, Frederick Arthur Brookfield, Christian Bubert, Mark Peter Ridgill
  • POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS
    Publication number: 20230116403
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z??(I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Application
    Filed: December 1, 2020
    Publication date: April 13, 2023
    Inventors: Wesley P. Blackaby, Ekizabeth Jane Thomas, David james Hardick, Jon Shepherd, Frederick Arthur Brookfield, Christian Bubert, Mark Peter Ridgill
  • METTL3 INHIBITORY COMPOUNDS
    Publication number: 20230085408
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z5 (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity 10 is implicated.
    Type: Application
    Filed: April 3, 2020
    Publication date: March 16, 2023
    Inventors: Wesley Peter BLACKABY, David James HARDICK, Elizabeth Jane THOMAS, Frederick Arthur BROOKFIELD, Christian BUBERT, Jon SHEPHERD, Mark Peter RIDGILL
  • POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS
    Publication number: 20230002378
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z??(I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Application
    Filed: July 29, 2022
    Publication date: January 5, 2023
    Inventors: Wesley Peter Blackaby, Elizabeth Jane Thomas, David James Hardick, Jon Shepherd, Frederick Arthur Brookfield, Christian Bubert, Mark Peter Ridgill
  • HETEROARYL INHIBITORS OF PAD4
    Publication number: 20210299115
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: May 12, 2021
    Publication date: September 30, 2021
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • Heteroaryl inhibitors of PAD4
    Patent number: 11026937
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: June 8, 2021
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • HETEROARYL INHIBITORS OF PAD4
    Publication number: 20190358216
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: September 11, 2017
    Publication date: November 28, 2019
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • Sepiapterin reductase inhibitors
    Patent number: 9963462
    Abstract: Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: May 8, 2018
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Mark Joseph Tebbe, Holly Victoria Atton, Craig Avery, Steven Mark Bromidge, Mark Kerry, Adrian Kotei Kotey, Nathaniel J. Monck, Mirco Meniconi, Mark Peter Ridgill, Heather Tye, Eddine Saiah, Kai Peter Johnsson, Katarzyna Irena Gorska, Hairuo Peng, John Michael McCall
  • SEPIAPTERIN REDUCTASE INHIBITORS
    Publication number: 20170096435
    Abstract: Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 6, 2017
    Inventors: Mark Joseph Tebbe, Holly Victoria Atton, Craig Avery, Steven Mark Bromidge, Mark Kerry, Adrian Kotei Kotey, Nathaniel J. Monck, Mirco Meniconi, Mark Peter Ridgill, Heather Tye, Eddine Saiah, Kai Peter Johnsson, Katarzyna Irena Gorska, Hairuo Peng, John Michael McCall
  • Piperidines and related compounds for the treatment of Alzheimer's disease
    Patent number: 8389547
    Abstract: Compounds of formula (I) are modulators of gamma-secretase, and hence are useful in treatment of Alzheimer's disease.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: March 5, 2013
    Inventors: Yudith Garcia, Joanne Clare Hannam, Timothy Harrison, Christopher L. Hamblett, Jed L. Hubbs, Janusz Josef Kulagowski, Andrew Madin, Mark Peter Ridgill, Eileen Seward
  • Piperidines and related compounds for the treatment of dementia
    Patent number: 8222418
    Abstract: Compounds of formula I: modulate the action of gamma secretase, and hence find use in treatment of Alzheimer's disease and related conditions.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: July 17, 2012
    Assignee: Merck Sharp + Dohme Corp.
    Inventors: Joanne Clare Hannam, Sascha Hartmann, Andrew Madin, Mark Peter Ridgill
  • Piperidine derivatives for treatment of Alzheimer's disease
    Patent number: 7985758
    Abstract: Compounds of formula (I) modulate the activity of gamma secretase and hence find use in treatment or prevention of Alzheimer's disease and related conditions.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: July 26, 2011
    Assignee: Merck, Sharp & Dohme Limited
    Inventors: Andrew Madin, Mark Peter Ridgill, Janusz Josef Kulagowski
  • PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20100048623
    Abstract: Compounds of formula (I) are modulators of gamma-secretase, and hence are useful in treatment of Alzheimer's disease.
    Type: Application
    Filed: April 25, 2007
    Publication date: February 25, 2010
    Inventors: Yudith Garcia, Joanne Clare Hannam, Timothy Harrison, Christopher L. Hamblett, Jed L. Hubbs, Janusz Josef Kulagowski, Andrew Madin, Mark Peter Ridgill, Eileen Seward
  • Piperidines and related compounds for treatment of alzheimer's disease
    Patent number: 7638629
    Abstract: Compounds of formula I: selectively inhibit production of A?(1-42) and hence are useful in treatment or prevention of disease associated with deposition of ?-amyloid in the brain.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: December 29, 2009
    Assignee: Merck Sharp & Dohme Ltd,
    Inventors: Joanne Clare Hannam, Janusz Jozef Kulagowski, Andrew Madin, Mark Peter Ridgill, Eileen Mary Seward
  • PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF DEMENTIA
    Publication number: 20090239905
    Abstract: Compounds of formula I: modulate the action of gamma secretase, and hence find use in treatment of Alzheimer's disease and related conditions.
    Type: Application
    Filed: March 27, 2007
    Publication date: September 24, 2009
    Inventors: Joanne Clare Hannam, Sascha Hartmann, Andrew Madin, Mark Peter Ridgill
  • PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20090186919
    Abstract: Compounds of formula (I) modulate the activity of gamma secretase and hence find use in treatment or prevention of Alzheimer's disease and related conditions.
    Type: Application
    Filed: April 2, 2007
    Publication date: July 23, 2009
    Applicant: MERCK SHARP & DOHME LIMITED
    Inventors: Andrew Madin, Mark Peter Ridgill, Janusz Josef Kulagowski
  • Gamma-secretase inhibitors
    Patent number: 7514459
    Abstract: Compounds of formula I: are potent inhibitors of gamma-secretase and hence find use in treatment or prevention of diseases associated with deposition of ?-amyloid.
    Type: Grant
    Filed: September 16, 2004
    Date of Patent: April 7, 2009
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Ian James Collins, Joanne Clare Hannam, Andrew Madin, Mark Peter Ridgill
  • Cyclic sulfamides for inhibition of gamma-secretase
    Patent number: 7427621
    Abstract: Compounds of formula I: inhibit the processing of AP by gamma-secretase, and hence are useful for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: September 23, 2008
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Ian James Collins, Joanne Clare Hannam, Timothy Harrison, Andrew Madin, Mark Peter Ridgill